It also appears from the reports that the characteristics of tebuconazole render it very persistent (vP) and toxic (T) in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council [Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).]. The period of approval should be 10 years in consistency with the current practice under Directive 98/8/EC, since the conditions of Article 90(2) of Regulation (EU) No 528/2012 are not met. However, for the purpose of authorising products in accordance with Article 23 of Regulation (EU) No 528/2012, tebuconazole shall be considered as a candidate for substitution pursuant to Article 10(1)(d) of that Regulation.
Recital 6, Commission Implementing Regulation (EU) No 1038/2013 of 24 October 2013 approving tebuco…
In force
Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012…9023Law
Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 Decembe…Law
- celex=31976L0769
- celex=31991L0155
- celex=31993L0067
- celex=31993L0105
- celex=31993R0793
- celex=31994R1488
- celex=31998L0008
- celex=31999L0045
- celex=32000L0021
- num:eu=1976/769